• SELECT SITE CURRENCY
Select a currency for use throughout the site
Summary: Merck & Co. Inc. Dec 11
Standard & Poors, December 2011
The strong investment-grade rating on Whitehouse Station, N.J.-based Merck & Co. Inc. reflects its diverse portfolio of high-margin products and steady stream of new product launches, key elements supporting its "excellent" business risk profile (as defined in Standard & Poor's Ratings Services' criteria). A long history of conservative financial policies and solid cash flows that we expect to exceed capital spending and dividends by nearly $6 billion in 2011 underpin our "minimal" financial risk assessment (as defined in our criteria) on the company. Merck is the second-largest branded pharmaceutical company in the world, with human prescription pharmaceuticals providing 86% of all revenues and the bulk of profits and cash flow. Animal health and consumer health care operations, combined, account for...
Companies mentioned in this report are: Merck & Co. Inc.
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
This product consists of a Summary Analysis: Bi-annual (at least). An abbreviated analysis containing Standard & Poor's issuer credit ratings as of the time the article was published. The analysis includes a rating rationale - the basis on which the rating was assigned - and an outlook section if the issuer is not on CreditWatch. Financial statistics are not included.
Merck & Co. Inc.